Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


In patients with arterial hypertension (HT) heart is affected earlier and more often than other target organs, left ventricular hypertrophy (LVH) develops. Considering the proven link between the presence of LVH and increased cardiovascular risk, the deterioration of the clinical course and prognosis in HT patients, as well as a significant prognosis improvement in patients with LVH decrease, correction of modifiable risk factors (including uncontrolled HT) is getting extremely important. Organoprotective properties of drugs should be taken into account as one of the important parameters in the consideration of antihypertensive therapy. Major studies conducted in recent years have proven cardioprotective and angioprotective properties of angiotensin receptor blocker losartan, so it can be used as first-line therapy in patients with HT and LVH.

About the Authors

I. I. Chukaeva
Russian National Research Medical University named after N.I. Pirogov, Moscow
Russian Federation

Ya. G. Spiryakina
Russian National Research Medical University named after N.I. Pirogov, Moscow
Russian Federation


1. Shal'nova S.A., Konradi A.O., Karpov Ju.A., et al. Analysis of mortality from cardiovascular disease in 12 regions of the Russian Federation involved in the study "Epidemiology of cardiovascular disease in different regions of Russia". Russian Journal of Cardiology 2012; (5): 6-11. Russian (Шальнова С.А., Конради А.О., Карпов Ю.А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах российской федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России». Российский кардиологический журнал 2012; (5); 6-11).

2. Ford E.S., Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 2011;32:5-22.

3. Schillaci G., Verdecchia P., Porcellati C., et al. Continuous Relation Between Left Ventricular Mass and Cardiovascular Risk in Essential Hypertension. Hypertension 2000;35:580-6.

4. Ghali J, Kadakia S, Cooper R et al. Impact of left ventricular hypertrophy patterns on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17: 1277-82.

5. Kohara K, Zhao B, Jiang Y et al. Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Am J Cardiol 1999; 83 (3): 367-70.

6. Kannel WB. Left ventricular hypertrophy as a risk factor. J Hypertens 1991; 9 (Suppl 2): 3-9.

7. Fuster V, Rydn LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114: 257-354

8. Li Z, Dahlof B, Okin PM, Kjeldsen SE, et al. Bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. J Hypertens 2008; 26:1244-9.

9. Verdecchia P, Cavallini C, Pede S et al. The voltage of R-wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens 2009;27:1697-704.

10. Milani RV, Lavie CJ, Mehra MR, et al. Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol 2006; 97:959-63.

11. Giuseppe Manciaa, Stephane Laurentb, Enrico Agabiti-Roseic et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 2009; 27:2-7.

12. Levy D, Anderson KM, Savage DD et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 1987;60(7):560-5.

13. Konradi A.O., Zhukova A.V., Vinnik T.A. et al Structural and functional parameters of the myocardium in hypertensive patients, depending on the weight of the body, such as obesity and the state of carbohydrate metabolism. Arterial Hypertension 2002; 8(1): 12-6. Russian (Конради А.О., Жукова А.В., Винник Т.А. и др. Структурно-функциональные параметры миокарда у больных гипертонической болезнью в зависимости от массы тела, типа ожирения и состояния углеводного обмена. Артериальная гипертензия 2002; 8(1):12-6).

14. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001;37:429-32.

15. Ferrara LA, de Simone G, Pasanisi F, et al. Left Ventricular Mass Reduction During Salt Depletion in Arterial Hypertension. Hypertension 1984; 6: 755-9.

16. National guidelines for diagnosis and treatment of hypertension (4th revision). Systemic Hypertension 2010;(3):5-26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии (4й пересмотр). Системные Гипертензии 2010;(3):5-26).

17. Ostroumova O.D., Golovina O.V., Rolik N.L. Organoprotective effect of antihypertensive drugs: does it matter for clinical practice? Consilium Medicum 2004; (6):344-9. Russian (Остроумова О.Д., Головина О.В., Ролик Н.Л. Органопротективный эффект антигипертензивных препаратов: имеет ли это значение для клинической практики? Consilium Medicum 2004; (6):344-9).

18. Klingbeil A.U., Schneider M., Martus P. et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:1:41-6.

19. Dahlof B, Devereux R, Kjeldsen S et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359 (9311):995-1003.

20. Nichols W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005;18 (Pt 2):3-10.

21. Nedogoda S.V., Ledjaeva A.A., Chumachok E.V., Coma V.V. Correction capabilities of hyperuricemia with losartan in patients with hypertension and gout. System Hypertension 2011; 8(4): 64-8. Russian (Недогода С.В., Ледяева А.А., Чумачок Е.В., Цома В.В. Возможности коррекции гиперурикемии лозартаном у пациентов с артериальной гипертензией и подагрой. Системные Гипертензии 2011; 8(4): 64-8).

For citation:

Chukaeva I.I., Spiryakina Y.G. СARDIOPROTECTION IN PATIENTS WITH HYPERTENSION – THE ROLE OF LOSARTAN. Rational Pharmacotherapy in Cardiology. 2013;9(6):660-663. (In Russ.)

Views: 457

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)